A Closer Look: Alogliptin's Delay Accelerated Takeda's Pursuit Of Nycomed
This article was originally published in The Pink Sheet Daily
Takeda found itself desperate to fill gaps with Actos LOE looming and alogliptin faltering, hastening a 10-year conversation with Nycomed.
You may also be interested in...
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?